Zoetis Q1 revenue $2.2B (+10% reported, +12% operational); adj EPS $1.38, +5% reported

Zoetis Inc.

2024-Q1 EPS reported $1.31 revenue$2,190,000,000

Reported net income $599M ($1.31 diluted EPS) +9%; adjusted net income $634M ($1.38 adj EPS) +5% reported, +17% operational.
US segment revenue $1.2B (+16%), driven by Simparica Trio, Apoquel, Cytopoint, Librela, Solensia.
International segment revenue $1.0B (+3% reported, +8% operational); companion animal +14% operational.
FY 2024 guidance raised: revenue $9.05-9.20B, reported EPS $5.34-5.44, adj EPS $5.71-5.81; operational growth 8.5-10.5%.
Company to sell MFA portfolio and buy a manufacturing site in Australia for vaccine development.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Zoetis Inc. reported first quarter of 2024 results: revenue $2.2 billion, net income $599 million, EPS $1.31 per diluted share. Guidance raised.

Period: first quarter of 2024
Revenue: $2.2 billion
Net income: $599 million
EPS: $1.31 per diluted share
Guidance: raised
Result: reported results

Exact text from the filing

Exchange Act, except as expressly set forth by specific reference in such a filing. --- EX-99.1 (EX-99.1) --- Zoetis Announces First Quarter 2024 Results • Reports Revenue of $2.2 Billion, Growing 10%, and Net Income of $599 Million, or $1.31 per Diluted Share, Increasing 9% and 10%, Respectively, on a Reported Basis for First Quarter 2024 • Delivers 12%

View on SEC.gov

362 earnings releases filed in the last 30 days. Browse all earnings releases →

Zoetis Inc. filing history →

Source: SEC EDGAR

accession 0001555280-24-000247

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.